Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Akebia Therapeutics (AKBA) PT Raised to $7.50 at H.C. Wainwright
August 12, 2024 6:13 AM EDTH.C. Wainwright analyst Ed Arce raised the price target on Akebia Therapeutics (NASDAQ: AKBA) to $7.50 (from $6.00) while maintaining a Buy rating.
The analyst comments "Akebia is focused on the long game, with pre-commercial execution preparing for Vafseo as the standard-of-care. As previously announced, Akebia submitted its TDAPA application in June. Akebia expects to have a CPT code assigned in October 2024 and full TDAPA designation by January 1, 2025. In... More
